3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

06/16/2026, 3:30 AM • The Motley Fool

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals announced it will release Q1 2026 financial results on May 6, 2026, followed by a live webcast at 8 a.m. ET. The company is a biopharmaceutical firm focused on MASH treatment, with its FDA and European Commission-approved medication Rezdiffra (resmetirom) for moderate to advanced fibrosis cases, and an ongoing Phase 3 trial for cirrhosis treatment.

04/22/2026, 8:00 AM • GlobeNewswire

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.

03/31/2026, 8:49 PM • Benzinga

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Summit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.

03/25/2026, 5:24 PM • The Motley Fool

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

03/21/2026, 7:19 PM • The Motley Fool

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Madrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs to expand its MASH treatment pipeline. The deal includes a $60 million upfront payment with potential cumulative payments reaching $4.4 billion upon milestone achievement. Madrigal's pipeline now includes over 10 programs anchored by its approved drug Rezdiffra, with additional candidates including MGL-2086 (GLP-1 agonist) and Ervogastat (DGAT-2 inhibitor) in development.

02/11/2026, 5:00 AM • GlobeNewswire

Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?

Ten large-cap stocks experienced significant declines during the week of January 5-9, 2026. Notable losers include Madrigal Pharmaceuticals (down 11.57%), First Solar (down 14.46% following a Jefferies downgrade), Astera Labs (down 12.18%), and Roblox (down 9.99%). Other major decliners include CoStar Group, American International Group, NRG Energy, Las Vegas Sands, Johnson Controls International, and HDFC Bank. The declines were driven by analyst downgrades, leadership transitions, and executive changes.

01/11/2026, 12:01 PM • Benzinga

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. Madrigal plans to conduct drug-to-drug interaction studies and consult with the FDA on Phase 2 combination trial design in 2026.

01/09/2026, 8:00 AM • GlobeNewswire

Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize

The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.

01/02/2026, 1:29 PM • Benzinga

2 Predictions for Novo Nordisk in 2026

Novo Nordisk faces challenges in 2026 but shows potential for recovery through lower drug prices, new drug indications, and promising pipeline candidates like Amycretin, which could help stabilize revenue growth.

12/14/2025, 9:30 AM • The Motley Fool

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.

11/17/2025, 8:00 AM • GlobeNewswire

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals presented two-year data on Rezdiffra, demonstrating significant improvements in liver imaging tests and biomarkers for patients with compensated MASH cirrhosis, highlighting potential benefits across different patient populations.

11/10/2025, 8:00 AM • GlobeNewswire

CoreWeave and Madrigal’s Insider Trades Flash Bullish Signals

Recent insider trading activities reveal interesting signals for CoreWeave and Madrigal Pharmaceuticals. While CoreWeave insiders are selling shares after a significant stock price increase, Madrigal insiders are buying, signaling potential opportunities in AI infrastructure and biotech sectors.

09/10/2025, 9:27 AM • Investing

Madrigal (MDGL) Q2 Revenue Soars 1,313%

Madrigal Pharmaceuticals reported strong Q2 2025 performance, with GAAP revenue of $212.8 million for its MASH therapy Rezdiffra, exceeding estimates by 31.3%. The company saw rapid patient adoption, with over 23,000 patients on the drug and expanding commercial operations.

08/05/2025, 4:07 PM • The Motley Fool

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Madrigal Pharmaceuticals will release its Q2 2025 financial results on August 5, 2025, and host a live webcast at 8 a.m. Eastern Time to review financial and operating results.

07/25/2025, 8:00 AM • GlobeNewswire